Multicenter biomarker study of trastuzumab for HER2-positive gastric cancer

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2011
INTERVENTION: Trastuzumab‐containing chemotherapy CONDITION: HER2‐positive gastric cancer PRIMARY OUTCOME: Immunohistological changes in the expression level before, during, and after treastuzumab‐containing chemotherapy INCLUSION CRITERIA: 1. HER2‐positive gastric cancer 2. Trastuzumab‐containing chemotherapy 3. Available tumor samples before, during, and after treatment 4. Written informed consent
Epistemonikos ID: 6a143aad2213ab427bf944b73c9ae7ebdb5797ec
First added on: Aug 22, 2024